Omnitrope (somatropin) is a brand-name drug that’s prescribed for growth hormone deficiency and other conditions. It comes as a subcutaneous injection that’s typically given once daily. The dosage can ...

Omnitrope is a brand-name injectable solution prescribed for growth hormone deficiency in adults and children. It contains the active ingredient somatropin. Omnitrope may not be safe to receive during ...

The prescribed dosage for Omnitrope (somatropin) may depend on a person’s individual treatment plan. Factors like your medical history and body weight may affect your dosage of Omnitrope. Omnitrope ...

• Now approved in US for full range of reference product indications Princeton, New Jersey, August 31, 2011 - Sandoz announced today that the US Food and Drug Administration (FDA) has approved its ...

Novartis' generic drug unit Sandoz has won European Commission approval to market Omnitrope, a human growth hormone that will become the first new biosimilar to hit the market. Sandoz expects to waste ...

Omnitrope (somatropin) has potential interactions with other medications. For example, Omnitrope can interact with corticosteroids and certain diabetes medications. Doctors prescribe Omnitrope for ...

When Sarah Sellers heard on May 31 that the U.S. Food & Drug Administration had approved a generic-like version of human growth hormone (HGH), she was less than thrilled. The product, called Omnitrope ...

Sandoz (Holzkirchen, Germany), the generics arm of Novartis (Basel, Switzerland), received approval from the US Food and Drug Administration (Rockville, MD) for "Omnitrope" (somatropin [rDNA origin]), ...

SAN FRANCISCO (CBS.MW) -- Sandoz, a unit of Novartis , announced Thursday that the U.S. Food and Drug Administration has deferred its decision on the company's application for Omnitrope. Omnitrope is ...

PRINCETON, N.J. The Food and Drug Administrations has approved two new uses for what remains, thus far, the only biosimilar on the U.S. market. Sandoz, the generics arm of Swiss drug maker Novartis, ...

The US Food and Drug Administration has approved the first ever ‘follow-on biologic’ medicine, Sandoz’ Omnitrope, but the development should not be read as an opening up of the marketplace for this ...

Holzkirchen, Germany-based Sandoz, the generics division of Switzerland’s largest drugmaker Novartis, has filed a lawsuit against the US Food and Drug Administration seeking a ruling on its pending ...